CFX - CFX STOCK NEWS

Colfax Corporation (NYSE: CFX) will announce its third-quarter 2021 financial results on November 4, 2021. A public conference call is scheduled for 8:00 a.m. Eastern, accessible via phone and webcast. The earnings release and any supplemental information will be available on Colfax's website prior to the call. Additionally, Colfax is undergoing a strategic separation into two independent companies focusing on specialty medical technologies and fabrication technologies, aiming to enhance value creation by Q1 2022.

DJO, a subsidiary of Colfax Corporation (NYSE: CFX), has launched the MedShape® DynaNail Hybrid™ Fusion System, enhancing its foot and ankle product line. This innovative system combines dynamic compression with an easy insertion design, crucial for subsiding foot deformities through subtalar fusion surgery. The DynaNail Hybrid maintains compression throughout healing, utilizing an adaptive mechanism to ensure optimal bone contact. DJO emphasizes its commitment to advanced medical technology aimed at improving patient recovery times and outcomes.

DJO, a subsidiary of Colfax Corporation (NYSE: CFX), unveiled its EMPOWR Dual Mobility™ at the 2021 AAOS Annual Meeting. This innovative product targets joint stability for primary and revision hip procedures, expected to see a dual mobility cup usage rise from 10% to 16% in elective cases over three years. The product features enhanced liner seating confirmation and a robust locking mechanism to reduce risks related to joint malseating. Its unique design and instrumentation aim to provide a comprehensive solution for surgeons, further solidifying DJO's presence in the orthopedic market.

Colfax Corporation (NYSE: CFX) announced the pricing of an underwritten secondary offering of 6,544,522 shares at $43.90 each, with shares expected to be delivered around August 2, 2021. The proceeds will go entirely to the Selling Stockholders, as Colfax will not sell any shares or receive proceeds. This offering is made under a shelf registration statement filed with the SEC, effective since February 18, 2021. Morgan Stanley is the sole book-running manager.

Colfax Corporation (NYSE: CFX) announced an underwritten secondary offering of 6,544,522 shares of its common stock by certain stockholders. The company will not receive any proceeds from this offering, as all net proceeds will go to the selling stockholders. Morgan Stanley is the sole book-running manager for the offering. This follows a shelf registration statement filed with the SEC, which became effective in February 2021. The offering materials will be available on the SEC website and from Morgan Stanley.

Colfax Corporation (NYSE: CFX) has successfully completed its acquisition of Mathys AG Bettlach for approximately $285 million. The deal was financed by issuing 6,544,522 shares of Colfax common stock to Mathys's former owners, under Section 4(a)(2) of the Securities Act of 1933, indicating a private transaction. This acquisition aligns with Colfax's strategy to enhance its orthopedic and fabrication technology offerings, contributing to its broader goal of separating into two independent companies by early 2022 to unlock value in specialty medical technologies and fabrication technologies.

Colfax Corporation (NYSE: CFX) reported Q2 2021 earnings with a net income of $30 million, or $0.19 per share, a significant improvement from a loss in the prior year. Adjusted EPS surged to $0.56, exceeding previous guidance. Net sales reached $986 million, a 59% increase, with substantial growth in both Fabrication and MedTech segments. The company announced an agreement to acquire Mathys Bettlach AG for $285 million to enhance its MedTech business. Colfax raised its FY 2021 EPS outlook to $2.10-$2.20, with projected Mathys sales of $150 million in 2022.

Colfax Corporation (NYSE: CFX) will release its second quarter 2021 financial results on July 29, 2021. A public conference call is scheduled for 8:00 AM Eastern Time, accessible via phone or webcast on Colfax’s website. Details, including a replay link, will be available in the 'Investors' section. Colfax, recognized for its orthopedic and fabrication technology products, is in the process of separating into two independent companies focused on specialty medical technologies and fabrication technologies, aiming to enhance strategic growth potential.

Colfax Corporation (NYSE: CFX) reported a strong first quarter of 2021, with a net income of $27 million, translating to $0.19 EPS from continuing operations. Adjusted EPS rose to $0.44, beating prior guidance. Sales increased 8% to $879 million, driven by a 9% organic sales-per-day growth. The company raised its 2021 adjusted EPS outlook to $2.05-$2.15. Key developments included the acquisition of MedShape for $225 million, expanding its foot & ankle platform. The company expects to generate over $250 million in free cash flow this year.